Endostatin prevents abnormal blood vessel growth

Article

A research report published in the December issue of the FASEB Journal, describes a new experimental drug, endostatin, which can significantly reduce or eliminate abnormal blood vessel growth within the eye.

A research report published in the December issue of the FASEB Journal, describes a new experimental drug, endostatin, which can significantly reduce or eliminate abnormal blood vessel growth within the eye, thereby offering a possible treatment for advanced age-related macular degeneration (AMD).

Alexander Marneros and co-workers from the Harvard Medical School, US and Niigata University Postgraduate School of Medicine, Japan tested the effects of endostatin on mice lacking the naturally occurring substance and in normal mice. The mice without endostatin were found to be three times more likely to develop advanced AMD than normal mice.

The researchers concluded that endostatin functions as the body's own natural inhibitor of new blood vessel growth and thus presents a possible therapeutic option for macular degeneration.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.